Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
August 25, 2021 at 10:37 am
Share
Wuhan Hiteck Biological Pharma Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 225.544 million compared to CNY 192.340 million a year ago. Operating income was CNY 1.434 million compared to operating loss of CNY 2.938 million a year ago. Net income was CNY 7.217 million compared to net loss of CNY 3.779 million a year ago. Basic earnings per share from continuing operations was CNY 0.07 compared to basic loss per share from continuing operations of CNY 0.04 a year ago.
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical company. The Company operates five segments. The Biopharmaceutical segment is engaged in research, development, production and sales of biological products, and its primary product is mouse nerve growth factor for injection named Jinlujie. The Medical Technology Service segment is mainly involved in the technical development, technical consultation and technology transfer of chemical drugs. The In Vitro Diagnostic Reagents segment operates the research, development, production and sales of in vitro diagnostic reagents. The Pharmaceutical Sales and Wholesale segment is engaged in the sales and wholesale of pharmaceuticals. The Other segmentâs businesses include the cultivation and sales of Chinese herbal medicines, and the wholesale and retail of health products.